Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $5.1 million.

  • Ocular Therapeutix's Non Operating Income rose 13336.38% to $5.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 million, marking a year-over-year increase of 11876.64%. This contributed to the annual value of $4.1 million for FY2025, which is 11877.1% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Non Operating Income stood at $5.1 million, which was up 13336.38% from -$720000.0 recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Non Operating Income registered a high of $23.3 million during Q1 2021, and its lowest value of -$33.2 million during Q1 2024.
  • For the 5-year period, Ocular Therapeutix's Non Operating Income averaged around $3.2 million, with its median value being $1.7 million (2022).
  • In the last 5 years, Ocular Therapeutix's Non Operating Income soared by 97594.57% in 2021 and then plummeted by 34011.52% in 2023.
  • Ocular Therapeutix's Non Operating Income (Quarter) stood at $14.2 million in 2021, then plummeted by 73.1% to $3.8 million in 2022, then crashed by 340.12% to -$9.2 million in 2023, then soared by 123.86% to $2.2 million in 2024, then soared by 133.36% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q4 2025, -$720000.0 for Q3 2025, and -$173000.0 during Q2 2025.